Bauersachs J (2021) Heart failure drug treatment: the fantastic four. Eur Heart J 42(6):681–683

Article  PubMed  PubMed Central  Google Scholar 

Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, Burkhoff D, Zannad F, Udelson JE, Voors AA (2020) Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 17(10):641–655

Article  PubMed  Google Scholar 

Jentzer JC, DeWald TA, Hernandez AF (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56(19):1527–1534

Article  CAS  PubMed  Google Scholar 

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297(12):1319–1331

Article  CAS  PubMed  Google Scholar 

Imamura T, Kinugawa K (2016) Urine Aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, Tolvaptan in patients with congestive heart failure. Int J Mol Sci 17(1):105

Article  PubMed  Google Scholar 

Imamura T, Kinugawa K (2019) Update of acute and long-term tolvaptan therapy. J Cardiol 73(2):102–107

Article  PubMed  Google Scholar 

Yaku H, Kaneda K, Kitamura J, Kato T, Kimura T (2022) Kampo medicine for the holistic approach to older adults with heart failure. J Cardiol 80(4):306–312

Article  PubMed  Google Scholar 

Bailly C (2024) Efficacy and safety of the traditional herbal medication Chai-Ling-Tang (in China), Siryung-tang (in Republic of Korea) or Sairei-To (in Japan). J Ethnopharmacol 319(Pt 1):117127

Article  CAS  PubMed  Google Scholar 

Yaku H, Kato T, Morimoto T, Kaneda K, Nishikawa R, Kitai T, Inuzuka Y, Tamaki Y, Yamazaki T, Kitamura J, Ezaki H, Nagao K, Yamamoto H, Isotani A, Takeshi A, Izumi C, Sato Y, Nakagawa Y, Matoba S, Sakata Y, Kuwahara K, Kimura T (2023) Rationale and study design of the GOREISAN for heart failure (GOREISAN-HF) trial: a randomized clinical trial. Am Heart J 260:18–25

Article  PubMed  Google Scholar 

Jo M, Shibahara N (2014) Effect of Goreisan on the urinary concentrating ability and the expressions of aquaporins in 5/6 nephrectomized rats. Nihon Yakurigaku Zasshi 143(2):65–68

Article  PubMed  Google Scholar 

Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) el criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients–association between non-responders and chronic kidney disease. Circ J 77(2):397–404

Article  CAS  PubMed  Google Scholar 

Kakeshita K, Imamura T, Onoda H, Kinugawa K (2023) Impact of Goreisan upon aquaporin-2-incorporated aquaresis system in patients with congestive heart failure. CEN Case Rep 12(1):73–77

Article  PubMed  Google Scholar 

Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ (2020) Cardiac natriuretic peptides. Nat Rev Cardiol 17(11):698–717

Article  CAS  PubMed  Google Scholar 

Oh YC, Jeong YH, Ha JH, Cho WK, Ma JY (2014) Oryeongsan inhibits LPS-induced production of inflammatory mediators via blockade of the NF-κB, MAPK pathways and leads to HO-1 induction in macrophage cells. BMC Complement Altern Med 14:242

Article  PubMed  Google Scholar 

Ahn YM, Cho KW, Kang DG, Lee HS (2012) Oryeongsan (Wulingsan), a traditional Chinese herbal medicine, induces natriuresis and diuresis along with an inhibition of the renin–angiotensin–aldosterone system in rats. J Ethnopharmacol 141(3):780–785

Article  PubMed  Google Scholar